• Wednesday, 26 June 2019

Delivra publishes positive results utilizing its novel platform technology for Varicose Veins


Jan 11, 2019 (6 months ago) |
TORONTO: Delivra Corp. (TSXV: DVA - Delivra or the Company) today announced the publication of positive data from a clinical study demonstrating the safety and efficacy to treat chronic venous insufficiency of lower limbs, using the LivReliefTM Varicose Vein Cream over-the-counter product. These results were published in the respected peer-reviewed scientific journal, PLOS ONE.
In a human clinical setting, undertaken by an independent third-party medical clinic, LivReliefTM Varicose Vein Cream provided significant therapeutic improvement in the treated lower limbs after six weeks of treatment. In the study, LivReliefTM Varicose Vein Cream was tested in humans with severe lower limb pain. This exemplifies Delivra's unique technology, with its multi-laminar systems which is capable of gradually releasing the active ingredient to the area of need, yielding quicker and longer lasting relief.

This impressive data further validates Delivra's platform technology, offering patients an effective, safe and convenient over-the-counter cream for varicose vein treatment. Our robust over-the-counter product development and pharmaceutical pipeline of high-value innovative products provide an array of unique commercialization opportunities. LivReliefTM Varicose Vein Cream, along with LivReliefTM Pain Relief Cream, LivReliefTM Extra Strength Chronic Angry Pain Relief Cream and LivReliefTM Sports & Active Pain Relief Cream can be found in over 6,000 retail outlets across Canada, said Dr. Joseph Gabriele, CEO of Delivra.

Like This Article?
Delivra publishes positive results utilizing its novel platform technology for Varicose Veins

contact Post your comment

category Read other Business World stories

home page Visit Home Page for latest updates